Search results
Results from the WOW.Com Content Network
Hypromellose , short for hydroxypropyl methylcellulose (HPMC), is a semisynthetic, inert, viscoelastic polymer used in eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products.
Lacrisert, manufactured by Aton Pharma, is a formulation of HPC used for artificial tears.It is used to treat medical conditions characterized by insufficient tear production such as keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis.
The main risk factor is a history of diabetes mellitus type 2. [4] Occasionally it may occur in those without a prior history of diabetes or those with diabetes mellitus type 1. [3] [4] Triggers include infections, stroke, trauma, certain medications, and heart attacks. [4] Other risk factors: Lack of sufficient insulin (but enough to prevent ...
Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.
[1] Protamine insulin was first created in 1936 and NPH insulin in 1946. [1] It is on the World Health Organization's List of Essential Medicines. [4] NPH is an abbreviation for "neutral protamine Hagedorn". [1] In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Elliott Proctor Joslin (June 6, 1869 – January 28, 1962) was the first medical doctor in the United States to specialize in diabetes and was the founder of the present-day Joslin Diabetes Center in Boston, Massachusetts.
Regular insulin is used for the long-term management of diabetes. [5] It is the treatment of choice for the two diabetic emergencies diabetic ketoacidosis and hyperosmolar hyperglycemic states. [5] It may also be used in combination with glucose to lower potassium levels in those with hyperkalemia. [6]
The first cost-effectiveness analysis of this nature was conducted from a societal perspective in the Swedish setting in 2013, finding that insulin degludec would be cost-effective relative to insulin glargine in the treatment of type 1 diabetes, and type 2 diabetes as part of either a basal or basal-insulin regimen. [28]